Retatrutide 10mg / 20mg / 30mg / 40mg / 60mg
Also known as Reta
Investigational triple agonist targeting GLP-1, GIP and glucagon receptors — 20mg, 30mg, 40mg and 60mg lyophilised vials at 99%+ purity for in vitro research.
Made to order: we reconstitute your peptide under sterile conditions and load it into a dial-a-dose Quick Pen, sent in discreet packaging with screw-on needles and a clicks-per-mg guide. Allow extra prep time versus a vial.
For In Vitro Use Only — Not for Human Use
Factory independent testing is reviewed for every batch, and we go the extra mile with our own independent HPLC & mass-spec testing in Europe. Where our certificate has been published, it is batch-numbered so you can match it to your vial.
Overview
Retatrutide (LY-3437943) is an investigational triple-receptor agonist that combines activity at the GLP-1, GIP and glucagon receptors in a single 39-residue peptide backbone. Supplied as a sterile lyophilised powder in 20mg, 30mg, 40mg and 60mg vials, each batch is verified to 99%+ purity by RP-HPLC and mass spectrometry.
Research
Retatrutide is used in vitro to study the combined pharmacology of incretin (GLP-1, GIP) and glucagon receptor signalling in a single molecule. Research groups compare it head-to-head against dual agonists (e.g. Tirzepatide) to characterise receptor bias, cAMP response, and peptide stability across long incubation windows.
